HCA Healthcare (HCA) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 22, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Erica Rossitto, Svp & Chief Nurse Executive sold 3,500 shares at $505.81 ($1.8M).
- Trade date
- Nov 10, 2026
- Disclosed to the SEC
- Nov 10, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All HCA insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
HCA insider transactions (Form 4)
Open-market purchases and sales. 76 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 10SEC | Erica RossittoSvp & Chief Nurse Executive | Sell | 3,50013,426 held (−21%) | $505.81 | $1.8M | -8.7% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 10,000 | $514.07 | $5.1M | -10.2% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 7,59517,786 held (−30%) | $494.91 | $3.8M | -6.7% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 6,30211,484 held (−35%) | $493.58 | $3.1M | -6.5% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 2,69225,381 held (−10%) | $495.85 | $1.3M | -6.9% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 1,68429,139 held (−5%) | $498.00 | $839K | -7.3% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 1,48410,000 held (−13%) | $491.98 | $730K | -6.2% | — |
| Nov 6SEC | Michael J. SchlosserEvp And Chief Clinical Officer | Sell | 1,2001,443 held (−45%) | $494.65 | $594K | -6.7% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 1,06628,073 held (−4%) | $496.92 | $530K | -7.1% | — |
| Nov 6SEC | Jon M. FosterCOO | Sell | 89030,823 held (−3%) | $498.97 | $444K | -7.5% | — |
| Feb 18SEC | Michael R. McAleveyGeneral Counsel | Sell | 1,6948,853 held (−16%) | $533.37 | $904K | -13.5% | — |
| Feb 12SEC | Jennifer BerresSvp & Chief Human Res. Officer | Sell | 4,01011,993 held (−25%) | $526.16 | $2.1M | -12.3% | — |
| Feb 12SEC | Christopher F. WyattSvp & Controller | Sell | 4,00044,379 held (−8%) | $505.00 | $2.0M | -8.6% | — |
| Feb 12SEC | Jennifer BerresSvp & Chief Human Res. Officer | Sell | 4,01016,003 held (−20%) | $503.00 | $2.0M | -8.2% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 14,71660,437 held (−20%) | $502.95 | $7.4M | -8.2% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 7,39548,040 held (−13%) | $500.69 | $3.7M | -7.8% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 6,18941,851 held (−13%) | $500.02 | $3.1M | -7.7% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 5,16236,689 held (−12%) | $498.80 | $2.6M | -7.5% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 5,00255,435 held (−8%) | $502.15 | $2.5M | -8.1% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 4,29332,396 held (−12%) | $498.12 | $2.1M | -7.3% | — |
| Feb 5SEC | Michael S. CuffeEvp And Chief Clinical Officer | Sell | 1,50030,003 held (−5%) | $498.09 | $747K | -7.3% | — |
| Feb 5SEC | Samuel N. HazenCEO | Sell | 12032,276 held (−0%) | $497.18 | $60K | -7.2% | — |
| Nov 5SEC | Michael R. McAleveyGeneral Counsel | Sell | 3,8923,487 held (−53%) | $473.79 | $1.8M | -2.6% | — |
Similar past setups: not applicable. HCA has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with HCA in the Research Lab
HCA has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
HCA Healthcare insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $47.5M of HCA stock on the open market; P/E 16.1 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
HCA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $18.3M | 10 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $29.3M | 12 |
| Q4 2025 | — | 0 | $1.8M | 1 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 HCA Healthcare insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $47.5M. 0 of 23 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
HCA earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 27, 2026 | +3.1% | None | -0.4%S&P +0.9% | pending |
| Jul 24, 2026 | -8.3% | None | +3.5%S&P +0.1% | +9.6% |
| Jul 14, 2026 | -0.2% | None | -3.0%S&P +0.8% | +6.8% |
| Apr 24, 2026 | -6.2% | None | -6.0%S&P +0.9% | -12.0% |
| Jan 27, 2026 | +0.1% | None | +4.0%S&P +0.4% | +7.8% |
| Oct 24, 2025 | +3.3% | None | +6.3%S&P +2.0% | +10.0% |
| Jul 25, 2025 | -9.8% | None | -0.3%S&P +0.4% | +18.9% |
| Apr 25, 2025 | +0.9% | None | -2.8%S&P +0.8% | +14.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
HCA short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded HCA
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | -1.8% |
Insiders at HCA Healthcare
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Samuel N. HazenCEO | — | $21.5M | Feb 12, 2026 | — | — |
| Jon M. FosterCOO | — | $15.9M | Nov 6, 2026 | — | — |
| Jennifer BerresSvp & Chief Human Res. Officer | — | $4.1M | Feb 12, 2026 | — | — |
| Michael R. McAleveyGeneral Counsel | — | $2.7M | Aug 28, 2026 | — | — |
| Christopher F. WyattSvp & Controller | — | $2.0M | Feb 12, 2026 | — | — |
| Erica RossittoSvp & Chief Nurse Executive | — | $1.8M | Nov 10, 2026 | — | — |
| Michael S. CuffeEvp And Chief Clinical Officer | — | $747K | Feb 12, 2026 | — | — |
| Michael J. SchlosserEvp And Chief Clinical Officer | — | $594K | Nov 17, 2026 | — | — |
| Patricia F. Elcan10% Owner | — | — | Nov 6, 2026 | — | — |
| Thomas F. Frist IIIDirector | — | — | Nov 6, 2026 | — | — |
| Mike A. MarksCFO | — | — | Nov 3, 2026 | — | — |
| William R. FristDirector | — | — | Apr 30, 2026 | — | — |
| John ChidseyDirector | — | — | Apr 30, 2026 | — | — |
| Nancy Ann DeparleDirector | — | — | Apr 30, 2026 | — | — |
| Hugh F. JohnstonDirector | — | — | Apr 30, 2026 | — | — |
| Michael W. MichelsonDirector | — | — | Apr 30, 2026 | — | — |
| Wayne Joseph RileyDirector | — | — | Apr 30, 2026 | — | — |
| Andrea B. SmithDirector | — | — | Apr 30, 2026 | — | — |
| II Holding Frisco10% Owner | — | — | Feb 10, 2026 | — | — |
| II Holding Hercules10% Owner | — | — | Feb 10, 2026 | — | — |
| Thomas F. Frist Jr.10% Owner | — | — | Feb 10, 2026 | — | — |
Board links: companies that share insiders with HCA
Directors and executives who filed Form 4s for HCA and another company in the last 12 months.
- DISWalt Disney Hugh F. Johnston Director here · CFO at DIS · latest filing Apr 30, 2026
- NCLHNorwegian Cruise Line John Chidsey Director here · CEO, President at NCLH · latest filing May 26, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
HCA stock: common questions
Are HCA Healthcare insiders buying HCA stock?
No. No HCA Healthcare insider reported an open-market purchase of HCA in the past 12 months.
Are HCA Healthcare insiders selling HCA stock?
8 insiders reported sales worth $47.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is HCA's P/E ratio?
HCA trades at about 16.1 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is HCA's 52-week range?
Over the past year HCA has traded between $359.93 and $542.23. It last closed at $461.58 on Nov 19, 2026.